Pioneering breast cancer test now available in UK
Summary by AI BETAClose X
10 November 2026
("EDX Medical" or the "Group" or "Company")
PIONEERING BREAST CANCER TEST NOW AVAILABLE FOR UK PATIENTS
CAMBRIDGE, UK: EDX Medical Group plc, which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, announces the Company is launching in the UK the first prognostic test that assesses both short and long-term risk of breast cancer recurrence. The test provides an assessment of long-term risk up to 15 years.
The Caris MI Clarity test leverages AI to transform how the risk of breast cancer recurrence is understood for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer, and has been validated by robust clinical data from tens of thousands of participants in clinical trials1 &2. The test is applied at the time of initial diagnosis.
EDX Medical has entered into an agreement with Caris Life Sciences, a leading US-based next-generation AI TechBio and precision medicine company, to supply the test in the UK.
Professor Sir Chris Evans, founder and chief scientific officer of EDX Medical, commented: “Bringing this truly pioneering test to the UK offers breast cancer patients and their doctors the opportunity to gain invaluable insight into the risk, both short and long term, of disease recurring. This test is a very significant step forward in terms of risk assessment and treatment planning for those patients.”
Dr Mike Hudson, chief executive, EDX Medical, commented: “MI Clarity fits superbly into our portfolio of advanced diagnostic tests, which provide doctors and their patients the most accurate digital diagnostic tools to inform treatment decisions.”
"Breast cancer clinicians have long been forced to make some of the most consequential treatment decisions with an incomplete picture of how recurrence risk changes over time," said George W. Sledge, Chief Medical Officer at Caris. "Caris MI Clarity is designed to bring early and late distant recurrence risk together in a single test at the time of initial diagnosis, when treatment decisions matter most. By leveraging AI on tumour pathology sample combined with clinical data, Caris MI Clarity has the potential to fundamentally improve how we personalize care for postmenopausal patients with HR-positive/HER2-negative, node-negative breast cancer."
For patients with early-stage breast cancer, accurately assessing the risk of distant recurrence is essential, as distant recurrence is the primary driver of mortality and is considered to be a key factor in treatment decisions.
Using tests currently available, clinicians frequently evaluate early and late distant recurrence risk separately, adding complexity to treatment planning. The Caris MI Clarity test is based on a multimodal Artificial Intelligence (AI) model integrating image, clinical and molecular data to assess both short and long-term risk at the time of diagnosis.
The test provides distinct risk stratification into low- or high-risk categories for both early (0–5 years) and late (5–15 years) distant recurrence, enabling clinicians to understand how recurrence risk may unfold over time.
References:
- Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Jr., Dees, E. C., Goetz, M. P., Olson, J. A., Jr., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., Ravdin, P. M., . . . Sledge, G. W., Jr. (2018). Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med, 379(2), 111-121. https://doi.org/10.1056/NEJMoa1804710
- Mamounas, E. P., Bandos, H., Rastogi, P., Lembersky, B. C., Jeong, J. H., Geyer, C. E., Jr., Fehrenbacher, L., Chia, S. K., Brufsky, A. M., Walshe, J. M., Soori, G. S., Dakhil, S. R., Wade, J. L., 3rd, McCarron, E. C., Swain, S. M., & Wolmark, N. (2023). Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst, 115(11), 1302-1309. https://doi.org/10.1093/jnci/djad078
Contacts
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer)
|
+44 (0)7812 345 301 |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
Media House International |
|
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609
|
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
About EDX Medical Group plc
The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyse and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 12 minutes ago AVI Global Trust
- 22 minutes ago LSL Property Services
- 25 minutes ago Bluebird Merchant Ventures (DI)
- 36 minutes ago Power Probe PLC
- 37 minutes ago Origin Enterprises (CDI)